Crinetics Pharmaceuticals (CRNX) Total Liabilities (2017 - 2026)

Crinetics Pharmaceuticals' Total Liabilities history runs 10 years deep, the most recent figure standing at $120.7 million for Q1 2026.

• In Q1 2026, Total Liabilities rose 12.44% year-over-year to $120.7 million; the TTM figure through Mar 2026 stood at $120.7 million (up 12.44% YoY), while the FY2025 annual figure was $134.2 million, up 22.21% from the prior year.
• Total Liabilities was $120.7 million for Q1 2026 at Crinetics Pharmaceuticals, down from $134.2 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $134.2 million in Q4 2025 to a low of $30.2 million in Q1 2022.
• Historically, Total Liabilities has averaged $83.8 million across 5 years, with a median of $103.2 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Total Liabilities surged 206.48% in 2024, then grew 3.98% in 2025.
• A 5-year view of Total Liabilities shows it stood at $35.8 million in 2022, then soared by 168.49% to $96.2 million in 2023, then grew by 14.07% to $109.8 million in 2024, then advanced by 22.21% to $134.2 million in 2025, then dropped by 10.06% to $120.7 million in 2026.
• The last three Total Liabilities figures came in at $120.7 million (Q1 2026), $134.2 million (Q4 2025), and $123.9 million (Q3 2025), per Business Quant data.